Human Biomarkers of Rapid Antidepressant Effects
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Mood disorders such as major depressive disorder (MDD) and bipolar disorder (BD)—and their consequent effects on the individual and society—are among the most disabling and costly of all medical illnesses. While a number of antidepressant treatments are available in clinical practice, many patients still undergo multiple and lengthy medication trials before experiencing relief of symptoms. A tremendous need therefore exists to improve current treatment options, and to facilitate more rapid, successful treatment in patients suffering from the deleterious neurobiological effects of ongoing depression. Towards that end, ongoing research is exploring the identification of biomarkers that may be involved in prevention, diagnosis, treatment response, severity, or prognosis of depression. Biomarkers evaluating treatment response will be the focus of this review, given the importance of providing relief to patients in a more expedient and systematic manner. A novel approach to developing such biomarkers of response would incorporate interventions with a rapid onset of action—such as sleep deprivation or intravenous drugs (e.g. ketamine or scopolamine). This alternative translational model for new treatments in psychiatry would facilitate shorter studies, improve feasibility, and increase higher compound throughput testing for these devastating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression, chronic diseases, and decrements in health: results from the World Health Surveys
Moussavi, S., Chatterji, S., Verdes, E., Tandon, A., Patel, V., & Ustun, B. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61415-9 · Cited by 4,070
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 1×
“The Val66Met SNP has been linked to psychiatric disorders and impaired trafficking/regulation of BDNF (36).”
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationSleep and Psychiatric Disorders: A Meta-analysis
Benca, R. M. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080059010 · Cited by 1,468 · cited 1×
“Sleep Deprivation: Sleep Architecture Sleep disturbances play a prominent role in diagnostic criteria for MDD, and abnormalities can include shortening of REM latency, increased REM density, overall disturbance of sleep continuity (17,18), and reduced slow wave sleep (slow d electroencephalogram [EEG] activity) (19).”
Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders
Autry, A. E., & Monteggia, L. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005108 · Cited by 1,390 · cited 1×
“Sleep Deprivation: Neurotrophic Factors One of the most studied neurotrophic factors in mood disorders is brain-derived neurotrophic factor (BDNF) (23).”
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Brunoni, A. R., Lopes, M., & Fregni, F. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009309 · Cited by 972
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 1×
“A recent post hoc analysis of BD-I or -II subjects pooled from two randomized and placebo-controlled studies (57,58) showed that, compared with those with FHN, subjects with FHP had attenuated psychotomimetic and dissociative scores (but not dysphoria) in response to ketamine and had greater improvement on MontgomeryÅ…”
Self-citationFrontocingulate Dysfunction in Depression: Toward Biomarkers of Treatment Response
Pizzagalli, D. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.166 · Cited by 945
Castrén, E., & Rantamäki, T. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20758 · Cited by 864
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846 · cited 1×
“Lastly, a proton MRS study was conducted to predict treatment outcome after ketamine administration, given that GABA and Glx levels are reduced in the medial and dorsal anterolateral PFCs of patients with MDD (43).”
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 1×
“A recent post hoc analysis of BD-I or -II subjects pooled from two randomized and placebo-controlled studies (57,58) showed that, compared with those with FHN, subjects with FHP had attenuated psychotomimetic and dissociative scores (but not dysphoria) in response to ketamine and had greater improvement on MontgomeryÅ…”
Self-citationModes and models of forebrain cholinergic neuromodulation of cognition
Hasselmo, M. E., & Sarter, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.104 · Cited by 733
Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings
Leppänen, J. M. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000191500.46411.00 · Cited by 632
Riedner, B. A., Vyazovskiy, V. V., Huber, R., Massimini, M., Esser, S., Murphy, M., & Tononi, G. (2007) · Sleep · doi:10.1093/sleep/30.12.1643 · Cited by 424 · cited 1×
“Prior research had shown that SWA and individual slow wave parameters are sensitive markers of cortical synaptic strength, thus serving as surrogate markers of central synaptic plasticity (46,47).”
Ketamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418
Self-citationFurey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417 · cited 3×
“BD) show similar magnitudes of treatment response to scopolamine, as do patients with and without a comorbid anxiety disorder (61).”
Self-citationLiu, R.-J., Lee, F. S., Li, X.-Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.030 · Cited by 403
The neurobiology and genetics of suicide and attempted suicide: A focus on the serotonergic system
Mann, J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00228-1 · Cited by 394
Esser, S. K., Hill, S. L., & Tononi, G. (2007) · Sleep · doi:10.1093/sleep/30.12.1617 · Cited by 315
Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Self-citationSalvadore, G., Cornwell, B. R., Colon-Rosario, V., Coppola, R., Grillon, C., Zarate, C. A., & Manji, H. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.014 · Cited by 277 · cited 3×
“This MEG study demonstrated that higher pretreatment levels of rostral ACC activity correlated positively with the magnitude of subsequent antidepressant response to ketamine (4 hours later), with healthy individuals displaying lower activity in this region (39).”
Self-citationDuncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., Yuan, P., Brutsche, N., Manji, H. K., Tononi, G., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000545 · Cited by 256 · cited 1×
“parameters (48), although the study was limited by the lack of a placebo control.”
Self-citationMathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
Self-citationLaje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F. J., Sanacora, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.031 · Cited by 213 · cited 1×
“the Val/Val BDNF allele were more likely to have an increased antidepressant response to ketamine than Met carriers (38).”
Self-citationPartial Sleep Deprivation as Therapy for Depression
Tölle, B. S. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780160037003 · Cited by 170
Benedetti, F., Serretti, A., Colombo, C., Campori, E., Barbini, B., di Bella, D., & Smeraldi, E. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1450 · Cited by 167
Machado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H. K., & Zarate, C. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04659 · Cited by 155
Self-citationScopolamine produces larger antidepressant and antianxiety effects in women than in men
Furey, M. L., Khanna, A., Hoffman, E. M., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.131 · Cited by 138 · cited 1×
“A differential response on the basis of gender is reported (72), with women showing greater improvement after scopolamine than men.”
Self-citationGillin, J. C., Buchsbaum, M., Wu, J., Clark, C., & Bunney, W. (2001) · Depression and Anxiety · doi:10.1002/da.1045 · Cited by 103 · cited 1×
“As noted earlier, higher pretreatment ACC metabolism predicted antidepressant response to both SD and some antidepressant treatments (40).”
Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder
Duncan, W. C., Selter, J., Brutsche, N., Sarasso, S., & Zarate, C. A. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.042 · Cited by 86
Self-citationBenedetti, F., Calabrese, G., Bernasconi, A., Cadioli, M., Colombo, C., Dallaspezia, S., Falini, A., Radaelli, D., Scotti, G., & Smeraldi, E. (2009) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2008.08.004 · Cited by 53
Cited by
The brain reward circuitry in mood disorders
Russo, S. J., & Nestler, E. J. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3381 · Cited by 1,870
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
“5 mg/kg) of ketamine produces robust and rapid antidepressant effects in two-thirds of patients with treatment resistant depression, and this response can last for over one week [9, 10, 15, 16].”
R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
Self-citationConvergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
“These established non-pharmacological interventions comprise a proof of principle for the more rapid relief of depressive symptoms and suggest the feasibility of designing rapid-acting antidepressant medications [17].”
BackgroundSelf-citation
Metadata
- Authors
- Zarate, C. A., Mathews, D. C., & Furey, M. L.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 73
- Issue
- 12
- Pages
- 1142-1155
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2023620267
- Cited by
- 89
- References
- 33
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.